{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"97.5","value":"0.0"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"97.5","value":"0.0"},{"groupId":"OG002","lowerLimit":"0.8","upperLimit":"90.6","value":"33.3"},{"groupId":"OG003","lowerLimit":"0.8","upperLimit":"90.6","value":"33.3"},{"groupId":"OG004","lowerLimit":"6.0","upperLimit":"61.0","value":"27.3"},{"groupId":"OG005","lowerLimit":"0.5","upperLimit":"71.6","value":"20.0"},{"groupId":"OG006","lowerLimit":"39.0","upperLimit":"94.0","value":"72.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"11"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"11"}],"units":"Participants"}],"description":"CBR was defined as the percentage of participants with a best overall response of minimal response (MR), partial response (PR), very good partial response (VGPR), complete response (CR) or stringent complete response (sCR) as determined by the investigator per IMWG response criteria for RRMM participants. MR=≥25% but ≤49% reduction of serum M-protein, reduction of 24-h urine by 50%-89% and if present at baseline, ≥50% reduction in the size (SPD) of soft tissue plasmacytomas. PR=≥50% reduction of serum M-protein, reduction in 24-h urinary M-protein by ≥90% or to \\<200mg/24h and if present at baseline,≥50% reduction in SPD of soft tissue plasmacytomas. VGPR=Serum+urine M-protein detectable by IFE but not electrophoresis or ≥90% reduction in serum M-protein+urine M-protein level \\<100mg/24h. CR=Negative IFE on serum/urine + disappearance of soft tissue plasmacytomas and ≤5% plasma cells in bone marrow aspirates. sCR=CR+normal FLC ratio, absence of clonal cells in bone marrow biopsy by IHC.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with RRMM received GEN3014 at a dose of 0.2/0.6 mg/kg by IV infusion in 28-day treatment cycles. Intraparticipant dose escalation was performed in this arm (i.e., dose was escalated from 0.2-0.6 mg/kg).","id":"OG000","title":"RRMM Dose Escalation: GEN3014 0.2/0.6 mg/kg"},{"description":"Participants with RRMM received GEN3014 at a dose of 2 mg/kg by IV infusion in 28-day treatment cycles.","id":"OG001","title":"RRMM Dose Escalation: GEN3014 2 mg/kg"},{"description":"Participants with RRMM received GEN3014 at a dose of 4 mg/kg by IV infusion in 28-day treatment cycles.","id":"OG002","title":"RRMM Dose Escalation: GEN3014 4 mg/kg"},{"description":"Participants with RRMM received GEN3014 at a dose of 8 mg/kg by IV infusion in 28-day treatment cycles.","id":"OG003","title":"RRMM Dose Escalation: GEN3014 8 mg/kg"},{"description":"Participants with RRMM received GEN3014 at a dose of 16 mg/kg by IV infusion in 28-day treatment cycles.","id":"OG004","title":"RRMM Dose Escalation: GEN3014 16 mg/kg"},{"description":"Participants with RRMM received GEN3014 at a dose of 24 mg/kg by IV infusion in 28-day treatment cycles.","id":"OG005","title":"RRMM Dose Escalation: GEN3014 24 mg/kg"},{"description":"Participants with anti-CD38 mAb-naive RRMM received GEN3014 IV infusion at a dose of 16 mg/kg in 28-day cycles during Expansion Part A.","id":"OG006","title":"RRMM Expansion Part A: GEN3014"}],"paramType":"NUMBER","populationDescription":"Full Analysis set included all enrolled participants who received at least 1 dose of trial drug (GEN3014 or daratumumab SC). Overall number of participants analyzed = participants evaluable for the outcome measure. As pre-specified, data for CBR was only collected and derived for RRMM participants.","reportingStatus":"POSTED","timeFrame":"Up to approximately 4 years 3 months","title":"Dose Escalation and Expansion Part A: Clinical Benefit Rate (CBR)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}